Luminary Therapeutics

Luminary Therapeutics develops innovative allogeneic and autologous CAR-T cell therapies using a proprietary gamma delta T cell expansion/manufacturing platform. Their lead programs target both solid tumors—such as NSCLC and colorectal cancer—and hematologic/B-cell-driven diseases. The company has received significant funding from ARPA-H to advance its mesothelin-targeting allogeneic CAR-T into the clinic, while its first-in-class triple receptor BAFF-CAR program has entered Phase I trials. Their approach aims to overcome key challenges of current cellular immunotherapies, including antigen escape, limited tumor infiltration, high relapse rates, manufacturing cost/complexity, and durability of response.